In the 2026 LDL (low-density lipoprotein) guidelines, does the ASCVD (atherosclerotic cardiovascular disease) risk calculated with the Pooled Cohort Equations refer to the 10‑year risk or the 30‑year risk?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

PREVENT Calculator Uses Both 10-Year and 30-Year ASCVD Risk

In the 2026 LDL guidelines, the PREVENT scoring system calculates both 10-year ASCVD risk (for all adults aged 30-79 years) and 30-year ASCVD risk (specifically for adults aged 30-59 years), with both timeframes used to guide treatment decisions 1, 2.

How the Risk Timeframes Are Applied

The PREVENT calculator is designed to provide dual risk estimates depending on patient age:

  • 10-year risk: Calculated for all adults aged 30-79 years and serves as the primary risk metric for treatment decisions
  • 30-year risk: Calculated specifically for adults aged 30-59 years to identify younger patients who may have low 10-year risk but substantial long-term risk 1, 2

Clinical Decision-Making Algorithm

For adults aged 30-59 years, treatment decisions incorporate both timeframes:

  1. Calculate both 10-year and 30-year ASCVD risk using PREVENT
  2. If 10-year risk is ≥7.5%, consider statin therapy based on standard risk thresholds
  3. If 10-year risk is <3% BUT 30-year risk is ≥10%, consider statin therapy - this represents a major expansion from prior guidelines 2, 3

This dual approach identifies approximately 15.6 million additional U.S. adults who would be eligible for statin consideration based on elevated 30-year risk despite having low 10-year risk 3. In fact, nearly twice as many adults aged 30-59 qualify based on 30-year ASCVD risk ≥10% compared to those with 10-year ASCVD risk ≥3% (15.6 million vs 7.9 million) 3.

For adults aged 60-79 years, only the 10-year risk is calculated and used for decision-making, as the 30-year calculation is not applicable to this age group 1.

Key Distinction from Pooled Cohort Equations

This differs from the older Pooled Cohort Equations, which only estimated 10-year risk (plus a less precise "lifetime risk"). The PREVENT calculator's inclusion of a specific 30-year risk estimate for younger adults represents a significant methodological advancement to capture long-term cardiovascular risk in populations where 10-year risk may underestimate true disease burden 1, 4.

References

1
Guideline

american association of clinical endocrinology consensus statement: algorithm for management of adults with dyslipidemia - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Related Questions

What is the 10‑year atherosclerotic cardiovascular disease (ASCVD) risk for a 59‑year‑old non‑Hispanic White female, non‑smoker, with untreated hypotension, total cholesterol 211 mg/dL, high‑density lipoprotein cholesterol (HDL‑C) 61 mg/dL, and low‑density lipoprotein cholesterol (LDL‑C) 145 mg/dL?
What is the 10‑year ASCVD (Atherosclerotic Cardiovascular Disease) risk for a 47‑year‑old white male, non‑smoker, without diabetes, on antihypertensive medication, with systolic blood pressure 136 mm Hg, total cholesterol 242 mg/dL, HDL‑cholesterol 48 mg/dL, LDL‑cholesterol 166 mg/dL, and chronic kidney disease (creatinine 1.3 mg/dL)?
What is the appropriate primary-prevention management for a patient with a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 8.5%?
What is the recommended management for a 35‑year‑old patient with BMI (body mass index) 32, family history of premature cardiovascular disease, blood pressure 138/88 mmHg, total cholesterol 232 mg/dL, LDL (low‑density lipoprotein) 125 mg/dL, HDL (high‑density lipoprotein) 34 mg/dL, triglycerides 342 mg/dL, and normal creatinine (renal function) and hemoglobin A1c (glycated hemoglobin)?
What is the appropriate treatment for a 46-year-old female who is hypertensive, non-diabetic, has a family history of diabetes and coronary artery disease, LDL cholesterol of 168 mg/dL, and a 10‑year ASCVD risk of less than 5%?
What are the diagnostic criteria for gambling disorder and how is severity classified?
Does my 23‑month‑old child with a facial rash have erythema infectiosum (slapped‑cheek disease)?
Does ashwagandha (Withania somnifera) improve male fertility, and what are the proposed mechanisms of action?
In an adult patient without sulfa allergy, normal renal function, and not pregnant, which is the more appropriate empiric antibiotic for infectious diarrhea: amoxicillin or cotrimoxazole (trimethoprim‑sulfamethoxazole)?
What baseline laboratory tests should be ordered for a patient with chronic kidney disease stage 3b?
In a patient with a known well‑differentiated neuroendocrine tumor who underwent microwave ablation of hepatic lesions, are heterogeneous, peripherally enhancing lesions in hepatic segments VII and V on a scan performed two months later consistent with expected post‑ablation changes or indicative of residual/metastatic disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.